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Abstract
Background: Although multidrug-resistant (MDR) gram-negative bacteremia (GNB) has been recognized as an
important cause of morbidity and mortality among abdominal solid organ transplant (ASOT) recipients, there are no
data on its prognostic factors after an interim standard definition of MDR was proposed in 2012. The objective of
this study was to describe the epidemiology, microbiology, and predictors of infection-related 30-day mortality in
ASOT recipients with MDR GNB.
Methods: We performed a retrospective, double-center analysis of ASOT patients with MDR GNB over a 13-year
study period. Univariate and multivariate analyses were performed to identify the risk factors for mortality.
Results: During the observational period, 2169 subjects underwent ASOT. Ninety-nine episodes of MDR GNB were
diagnosed in 91 (4.6%) ASOT recipients, with a predominance of E.coli (29 isolates, 29.3%) and A.baumanii (24
isolates, 24.2%). The median age of these 91 recipients was 45 years (interquartile range 35–54). Mortality after the
first episode of MDR GNB was 39.6% (36 deaths). The univariate analysis identified the following variables as
predictors of MDR GNB-related mortality: lung focus (P = 0.001),nosocomial origin (P = 0.002), graft from donation
after cardiac death or deceased donors (P = 0.023), presence of other concomitant bloodstream infection (P < 0.001),
temperature of 40 °C or greater at the onset of MDR GNB (P = 0.039), creatinine > 1.5 mg/dl (P = 0.006), albumin <
30 g/L (P = 0.009), platelet count < 50,000/mm3 (P < 0.001), and septic shock (P < 0.001). In the multivariate logistic
regression analysis, septic shock (odds ratio (OR) = 160.463, 95% confidence interval (CI) = 19.377–1328.832, P < .001),
as well as creatinine > 1.5 mg/dl (OR = 24.498, 95% CI = 3.449–173.998, P = 0.001), nosocomial origin (OR = 23.963,
95% CI = 1.285–46.991, P = 0.033), and presence of other concomitant bloodstream infections (OR = 27.074, 95% CI
= 3.937–186.210, P = 0.001) were the variables associated with MDR GNB-related 30-day mortality.
Conclusions: MDR GNB was associated with high morbidity and mortality in ASOT recipients, with a predominant
causative organisms being E.coli and A.baumanii. Nosocomial origin, as well as presence of other concomitant
bloodstream infections, increased creatinine level and septic shock were the main predictors of MDR GNB-related
30-day mortality.
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Background
Bloodstream infection (BSI) frequently complicates the
postoperative course and is the most frequent life-
threatening infectious complication after abdominal solid
organ transplantation (ASOT) [1–10]. The morbidity and
mortality rates have been reported to range from 4.5-69%
[2, 11–22] and 2.4–52% [2, 5, 6, 15, 16, 21, 23–30] in
ASOT recipients with BSI, respectively.
Significantly, recent reports have demonstrated a shift
in the distribution of BSI toward Gram-negative bacteria
as the predominant pathogens and multidrug-resistant
(MDR) gram-negative bacteremia (GNB) have emerged
frequently after transplantation [20, 31–33]. Among liver
recipients with BSI, 67% of Enterobacteria and 75% of
non-fermenters were MDR [31]. The mortality rate was
44.4 and 36.6% in MDR non-fermenters and P.aeruginosa
bacteremic transplant recipients, respectively [2, 34].
Aguiar EB et al. found that 26% of ASOT patients died
within 30 days of the diagnosis of the first episode of
bacteremia caused by extended-spectrum β-lactamase
(ESBL)-producing Enterobacteriaceae [35]. BSI or non-
BSI caused by carbapenem-resistant K.pneumoniae led to
a staggering up to 82% mortality after liver transplantation
[36–40]. The mortality due to extensively drug-resistant
A.baumannii infections, with 88% of these infections be-
ing ventilator-associated pneumonia, was 56% among
solid organ transplant (SOT) recipients [41].
Although the emergence of MDR GNB in SOT recipi-
ents has been demonstrated in multiple studies, current
information about predictors of mortality among these
patients is scarce, and mainly derives from studies which
did not use a standard definition for MDR or focused on
the individual microorganisms [42].
A group of international experts came together
through a joint initiative by the European and US Cen-
ters for Disease Control and Prevention in 2012. An
interim standard definition of MDR proposed by the
meeting was acquired non-susceptibility to at least
one agent in three or more antimicrobial categories
[43]. Reference 43 illustrated in detail the interim
standard definition of MDR of major gram-negative
bacteria, including Enterobacteriaceae, P.aeruginosa,
and A.baumannii. P.cepacia and O.anthropi were
defined as resistant to at least three of the antibiotics
as MDR P.aeruginosa and A.baumannii, respectively.
S.maltophilia was defined MDR as resistant to at least
three of the antibiotics (other than antipseudomonal
carbapenems) as MDR P.aeruginosa. After the use of
an interim standard definition for MDR [44], no study
has specifically been designed to identify the predic-
tors of mortality among ASOT recipients with all
types of MDR GNB so far. The purpose of this study
was to describe the epidemiology, microbiology, and
clinical outcomes of MDR GNB and determine the




This study was conducted at the Third Xiangya Hospital
(Changsha) of Central South University, and Zhongnan
Hospital (Wuhan) of Wuhan University, two tertiary
university referral hospitals in China. From January 1,
2003 to February 29, 2016, all episodes of MDR GNB
occurring in hospitalized ASOT recipients were
included. Recipients who were lost to follow-up or
moved out of the both hospitals within 30 days after
MDR GNB or who were recipients of multiorgan trans-
plants were excluded from the study. For the purposes
of this study, recipients were divided into two groups
according to their final outcomes: survival and death
within 30 days after the first episode of MDR GNB. The
two groups were compared to identify risk factors influ-
encing mortality.
No liver recipients received induction therapy. The
lymphocyte-depleting induction therapy was selectively
used in some kidney recipients at high risk for acute
rejection. All recipients enrolled were administered
maintenance immunosuppressive treatment consisting
of one to three drugs such as corticosteroids, a calcineurin
inhibitor (e.g., tacrolimus or cyclosporine), and antimeta-
bolic agents (e.g., mycophenolate mofetil, mizoribine, or
azathioprine). Second- or third-generation cephalosporins,
semisynthetic penicillins/beta-lactamase inhibitors, or
carbapenems, according to the pretransplant results of
cultures, were prescribed 1 h before liver transplantation
and additional dose 72 h posttransplantation. Second-
generation cephalosporins were prescribed 1 h before the
operation and additional dose 24 h posttransplantation for
kidney transplantation.
Study design and data collection
We conducted a retrospective study of ASOT recipients
who presented with MDR GNB to determine the
epidemiology of pathogens and risk factors for MDR
GNB-related 30-day mortality. The analysis of prognos-
tic factors included only the first episode of MDR GNB
from each patient that occurred during the observational
period.
The following baseline clinical, epidemiologic and
laboratory data were collected from patients’ medical
records: sex; age; type and date of transplantation; type
and date of diagnosis of MDR GNB; Non-fermentative
bacteremia or not; ESBL(+) rods or not; carbapenem-
resistant rods or not; results of antibiotic susceptibility
tests; site of primary infection; presence of other
concomitant BSI; empirical antimicrobial therapy; use of
central venous catheters; septic shock or death
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information. The laboratory data were obtained within
the first 24 h after the blood culture was drawn, consist-
ing of serum creatinine and albumin levels, white blood
cell, platelet and lymphocyte count. We also collected
serum creatinine level at the time point of 1 week after
MDR GNB. All patients were followed up for 30 days
from the first episode of MDR GNB.
Microbiologic methods
A 10-mL blood sample was injected into each bottle of a
set of aerobic and anaerobic blood culture bottles and
immediately transported to the clinical microbiology la-
boratory. Blood samples were loaded into the BACTEC
9120 blood culture system (Becton Dickinson, Cockeys-
ville, MD, USA). Bacterial identification was performed
by using the Vitek-2 system (bioMérieux, Craponne,
France). In vitro antimicrobial susceptibility tests of
blood isolates were performed by the Kerby-Bauer disc
diffusion method and the minimum inhibitory concen-
tration (MIC) was measured by agar dilution. The pro-
duction of ESBL was detected by the confirmatory
double-disk synergy test [45]. The interpretation of anti-
microbial susceptibility test results followed recommen-
dations of the National Committee for Clinical
Laboratory Standards [46], which was suitable for 2003
and the Clinical and Laboratory Standards Institute [47],
which was suitable for 2004–2016. Gram-negative bac-
teria with intermediate susceptibility to the antibiotics
was considered as resistance.
Definitions
The presence of BSI was defined according to the
criteria proposed by the Centers for Disease Control and
Prevention [48]. Appropriate empirical antimicrobial
therapy was defined as administration of antibiotics to
which the pathogen was susceptible in vitro within 48 h
after the blood culture was obtained [49]. BSI was con-
sidered as nosocomially acquired if positive blood
cultures were obtained in patients who had been hospi-
talized for 48 h or longer. Community-acquired BSI was
defined if positive blood cultures were obtained within
the first 48 h after hospital admission [18]. Bacteremia
was defined to be early-onset occurring within the first
2 months (60 days) or less of ASOT and late-onset infec-
tion occurred beyond this time point [13]. When a posi-
tive bacterium or fungus blood culture occurred in the
setting of documented MDR GNB, the modifier “pres-
ence of other concomitant BSI” was applied to that
infection.
Septic shock was diagnosed in recipients who had a
positive blood culture and occurred persistent dysfunction
of at least one organ owing to hypoperfusion unresponsive
to intravenous fluid challenge [50]. MDR GNB-related
mortality was regarded if death was correlated with
clinical signs of MDR GNB without evidence of any other
cause [51].
Statistical analysis
Statistical analyses were executed with the statistical
package SPSS for Windows, version 22.0 (IBM SPSS Sta-
tistics, IBM Corporation, Armonk, NY, United States).
Continuous variables were listed as means ± standard
deviations or medians (1st-3rd quartile) according to the
distribution. Category variables were compared by Pear-
son’s χ2 test or Fisher’s exact test when appropriate. To
determine the association between demo/clinical vari-
ables and MDR GNB-related 30-day mortality, all covar-
iates associated with a P value of <0.05 in the univariate
analysis were selected for multivariate logistic regression
analysis. The final model was obtained with a forward
stepwise regression approach. Odds ratio (OR) with 95%
confidence intervals (CI) for the effect of demographic,
clinical and laboratory predictors on mortality were eval-
uated using logistic regression. The method of multivari-
able multicollinearity diagnostics was used to detect if
any of the risk factors for bacteremia-associtated mortal-
ity including presence of other concomitant BSIs, noso-
comial infection, creatinine > 1.5 mg/dL and septic
shock was an independent risk factor. All P values were
bicaudate and a value of P < 0.05 was considered to be
statistically significant.
Results
During the 13-year study period, we performed 1681
ASOT in the Third Xiangya Hospital, including 1465
kidney, 210 liver, five simultaneous liver-kidney, and one
simultaneous kidney-pancreas transplantations, and 488
ASOT in Zhongnan Hospital, consisting of 346 kidney,
140 liver, and two simultaneous liver-kidney transplanta-
tions. A total of 327 episodes of BSI including
bacteremia and fungemia occurred in 227 (10.5%) of
2169 ASOT recipients.
A total of 168 episodes of GNB were diagnosed among
these patients. Ninety-nine MDR gram-negative isolates
were isolated from 91 (4.6%) ASOT recipients with BSI.
The median age of these 91 recipients was 45 years
(interquartile range 35–54) with a male predominance
(68.1%). A significantly higher proportion of liver recipi-
ents (44 [12.3%] of 357 patients) were affected by MDR
GNB when compared with renal patients (47 [2.6%] of
1812 subjects) (P < 0.001). The median time after the
transplantation for the diagnosis of MDR GNB was
26 days (interquartile range: 7–81 days). The median
time for the diagnosis of the first episode of MDR GNB
was significantly longer among renal recipients (69 days;
interquartile range: 27–184 days) than in liver recipients
(11 days; interquartile range: 3–26 days) (P < 0.001). Of
these 91 ASOT recipients, 74 were classified as
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nosocomially acquired MDR GNB with a mortality of
47.3% (35/74) which was higher than the mortality of
5.9% (1/17) caused by community-acquired MDR GNB.
Appropriate empiric antibiotic therapy was prescribed in
only 57 (62.6%) patients.
Seventy-eight cases (85.7%) had a fever at the onset of
MDR GNB. The predominant primary sites of infection
in the first episode of MDR GNB were lungs (40.7%)
and intra-abdomen/biliary tract (23.1%). Five (5.5%)
primary sites of infection were vascular catheters.
Eighty-three patients experienced a single episode of
MDR GNB and eight cases experienced two episodes.
Thirty-eight (41.8%), 73(80.2%) and 36 (39.6%) patients
infected by carbapenem-resistant rods, ESBL(+) rods
and non-fermenters, respectively. Thirty-five cases
(38.5%) experienced MDR GNB presenting with other
concomitant BSI. There were 33 (36.3%) septic shocks at
the onset of MDR GNB. MDR GNB-related 30-day mor-
tality after the first episode of MDR GNB was 39.6% (36
deaths). The demographic, clinical, and laboratory char-
acteristics of the patients are presented in Table 1.
Ninety-nine MDR gram-negative bacteria were iso-
lated from these 91 ASOT recipients with BSI, with a
predominance of E.coli (29 isolates, 29.3%), A.baumanii
(24 isolates, 24.2%), E.cloacae (11 isolates, 11.1%), and
K.pneumoniae (ten isolates, 10.1%). Table 2 listed in de-
tail the classification and percentage of 99 MDR gram-
negative bacteria isolated.
The association of the studied covariates with mortal-
ity after the first episode of MDR GNB by using the uni-
variate and multivariate analyses is shown in Table 3.
The univariate analysis identified the variables as predic-
tors of MDR GNB-related mortality included lung focus
(P = 0.001),nosocomial origin (P = 0.002), graft from do-
nation after cardiac death or deceased donors (P =
0.023), presence of other concomitant BSI (P < 0.001),
temperature of 40 C or greater at the onset of BSI (P =
0.039), creatinine > 1.5 mg/dl at onset of MDR GNB (P
= 0.006), albumin < 30 g/L (P = 0.009), platelet count <
50,000/mm3 (P < 0.001), and septic shock (P < 0.001). A
factor that tended to be associated with higher mortality
was lymphocyte count < 300/mm3 (P = 0.051). Septic
shock (OR = 160.463, 95% CI = 19.377–1328.832, P <
0.001), as well as creatinine > 1.5 mg/dl at onset of
bacteremia (OR = 24.498, 95% CI = 3.449–173.998, P =
0.001), nosocomial origin (OR = 23.963, 95% CI = 1.285–
446.991, P = 0.033), and presence of other concomitant
BSI (OR = 27.074, 95% CI = 3.937–186.210, P = 0.001)
remained statistical significance in the multivariate logis-
tic regression analysis. The method of multivariable mul-
ticollinearity diagnostics was used to detect if any of the
risk factors for bacteremia-associtated mortality includ-
ing presence of other concomitant BSIs, nosocomial in-
fection, creatinine > 1.5 mg/dL and septic shock was an
Table 1 Demographic, laboratory and clinical variables of 91
ASOT recipients with MDR GNB
Characteristics Value
Age, median years (IQR) 45 (35-54)
Sex, number of male (%) 62 (68.1)
Temperature of 40 °C or greater, no. of cases (%) 12 (13.2)
Nosocomial origin, no. of cases (%) 74 (81.3
Inappropriate antimicrobial use, no. of cases (%) 34 (37.4)
Septic shock, no. of cases (%) 33 (36.3)




The type of transplantation, no. of cases (%)
Liver 44 (48.4)
Kidney 47 (51.6)
Site of primary infection, no. of cases (%)
Lung 37 (40.7)
Intra-abdominal/biliary 21 (23.1)
Urinary tract 13 (14.3)
Vascular catheter 5 (5.5)
Gastrointestinal tract 3 (3.3)
Unknown 13 (14.3)
Type of organisms, no. of cases (%)
Monomicrobial 83 (91.2)
Polymicrobial 8 (9.8)
Non-fermentative bacteremia, no. of cases (%)
Yes 36 (39.6)
No 55 (60.4)
ESBL (+) rods, no. of cases (%)
Yes 73 (80.2)
No 18 (19.8)
Carbapenem-resistant rods, no. of cases (%)
Yes 38 (41.8)
No 53 (58.2)
Time of bacteremia onse, no. of cases (%)
< 2 months posttransplant (early-onset) 62 (68.1)
≥ 2 months posttransplant (late-onset) 29 (31.9)
Laboratory variables, no. of cases (%)
Platelet count < 50000/mm3 39 (42.9)
Lymphocyte count < 300/mm3 32 (35.2)
Albumin < 30 g/L 16 (17.6)
WBC count > 15000/mm3 27 (29.7)
Creatinine > 1.5 mg/dL at onset of bacteremia 42 (46.2)
Creatinine at 1 week after bacteremia
> 1.5 mg/dL 26 (28.6)
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independent risk factor. We found that all variance infla-
tion factors wrer less than 1.2, all condition indexs were
less than seven and none of eigenvalue was equal to 0,
which indicated that these risk factors were independent.
Discussion
MDR gram-negative isolates, including carbapenem-
resistant K.pneumoniae and ESBL- or carbapenemase-
producing Enterobacteriaceae, are an emergent problem,
with limited therapeutic options. It maybe prolong the
hospital stay, increase the difficulty of treatment and the
risk of death. SOT recipients are especially at high risk
for infection by MDR gram-negative bacteria due to
numerous hospitalizations, surgical interventions, preex-
isting and posttransplant immunosuppression, the use of
invasive devices and frequent antibiotic exposures.
Understanding the epidemiology and the risk factors
of mortality associated with MDR GNB may facilitate
guiding appropriate initiation of antibiotic therapy, and
reducing the risk factors associated with mortality [44].
Here we specially described a large retrospective cohort
of ASOT recipients and their incidence of all MDR GNB
over a 13-year period. E.coli and A.baumanii were the
predominant MDR gram-negative bacteria among these
ASOT population with BSI. Our data confirmed the pro-
found impact of MDR GNB on mortality. The incidence
of MDR GNB was higher in liver recipients (12.3%) than
in renal recipients (2.6%). More severe disease and
exposure to multiple antimicrobial therapies before and
after liver transplantation, technical complexity of liver
transplant surgery, prolonged operative time, more
transfusion during surgery, longer postoperative inten-
sive care unit stay and admission days, and invasive
diagnostic procedures after liver transplantation may
account for this difference.
To our best knowledge, this is the first study to specif-
ically address the risk factors for attributable mortality
among ASOT recipients with all types of MDR GNB,
after an interim standard definition of MDR was pro-
posed in 2012 [43]. Here, we observed an occurrence
rate of 4.6% and a mortality rate of 39.6% among ASOT
patients affected by MDR GNB, a finding consistent with
previous reports. This current analysis, however,
includes a larger number of ASOT recipients with all
types of MDR GNB than previous studies, which gener-
ally addressed only one type of MDR gram-negative
bacteria such as carbapenem-resistant K.pneumoniae or
ESBL-producing Enterobacteriaceae or all kinds of infec-
tions due to MDR gram-negative isolates [35–40, 52].
We found, in the current study, that nosocomial
origin, as well as the presence of other concomitant
bloodstream infections, increased creatinine level and
septic shock, all of which indicated a severity of illness,
more hospitalized or invasive procedures and particu-
larly difficult to treat, were the main predictors of MDR
GNB-related 30-day mortality. We found that septic
shock led to a 160-fold increase in mortality and was the
strongest predictor of patient outcomes in multivariate
models. This association of septic shock with mortality
echoed the findings of our previous study [53–55] and
other studies [26, 42, 56, 57] based on SOT recipients
with BSI. Septic shock is the most severe complication
in the context of BSI in SOT recipients and improving
the management of septic shock remains a great chal-
lenge [2, 42]. It is not surprising because septic shock
is a manifestation of the severity of illness. Aguiar EB
et al. also reported factors associated with clinical
severity including the Pitt bacteremia score and being
on mechanical ventilation at the time of infection
diagnosis were the main predictors of mortality in
SOT recipients with bacteremia caused by ESBL-
producing Enterobacteriaceae [35]. This finding can
alert clinicians to the importance of early therapy
[58], including protocolized resuscitation with intra-
venous fluids and early empirical antibiotic therapy,
which may reduce the mortality associated with
severe sepsis and septic shock, which occur in nearly
Table 1 Demographic, laboratory and clinical variables of 91
ASOT recipients with MDR GNB (Continued)
≤ 1.5 mg/dL 49 (53.8)
Missing due to death within 1 week after bacteremia 16 (17.6)
Related mortality, no. of cases (%) 36 (39.6)
ASOT abdominal solid organ transplantation, DCD donation after cardiac
death, ESBL extended-spectrum beta-lactamase, MDR multidrug-resistant, GNB
gram-negative bacteremia, IQR interquartile range, WBC white blood cells
Table 2 Classification and percentage of 99 multidrug-resistant
gram-negative bacteria isolated from 91 recipients with
bacteremias






P. aeruginosa 6 6.1
O.anthropi 4 4.0
K.ozaenae 2 2.0
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15% of bacteremic infections in SOT recipients and
have a mortality rate of 50% [7].
In our present study, nosocomially acquired MDR
GNB had a higher mortality of 47.3% than the mortality
of 5.9% caused by community-acquired MDR GNB,
which was consistent with a recent report from Thailand
in the general population suggesting that the mortality
in MDR hospital-acquired bacteremia was higher than
MDR community-acquired bacteremia (53% vs. 35%)
[59]. Thus, nosocomial infection was also associated
with MDR GNB-related mortality in the present study,
which was in line with a USA study of SOT recipients
with BSI conducted by Hsu J et al. [21]. MDR gram-
negative bacilli have emerged as a significant pathogen
responsible for nosocomially acquired infections [60]. It
is not surprising that nosocomial infection predicted
mortality given that it indicated more exposure to mul-
tiple antimicrobial therapies and particularly difficult to
treat. Other previous studies also claimed that when
compared to other BSI in SOT patients, nosocomial BSI
was associated with an increased risk of septic shock
and failure of clinical cure [2, 7, 61, 62]. Given nosoco-
mial MDR GNB can be limited by specific preventive
measures, we provided fertile ground that MDR GNB-
related morbidity and mortality after ASOT could be
further decreased [63].
We also revealed that increased serum creatinine level
affected survival of ASOT recipients with MDR GNB.
This finding was accordant with previous studies of SOT
recipients with BSI revealing that renal dysfunction was
related to increased mortality [5, 33, 53, 64]. A recent
study of SOT recipients with BSI also reported that renal
impairment (a serum creatinine level of >1.5 mg/dL)
was more frequent among non-survivors [42]. Renal in-
sufficiency was also reported as a predictor of mortality
among hematopoietic stem cell transplant patients with
invasive Aspergillosis infections [65–67]. There are
multiple etiologies for renal impairment in transplant
Table 3 Risk factors for bacteremia-related mortality in ASOT recipients with MDR GNB
Characteristics Related mortality Survival P OR (95% CI)
Total, n (%) 36 (39.6) 55 (60.4)
Univariate analysis
Age≥ 40 year 25 (69.4) 35 (63.6) 0.568
Male sex 24 (66.7) 38 (69.1) 0.808
Temperature≥ 40 °C 8 (22.2) 4 (7.3) 0.039
Inappropriate empirical antibiotics 14 (38.9) 20 (36.4) 0.808
Nosocomial infection 35 (97.2) 39 (70.9) 0.002
Graft from DCD or deceased donors 17 (47.2) 39 (70.9) 0.023
Liver transplant 20 (55.6) 24 (43.6) 0.266
Lung focus 22 (61.1) 15 (27.3) 0.001
Presence of other concomitant BSIs 22 (61.1) 13 (23.6) <0.001
Non-fermentative bacteremia 18 (50.0) 18 (32.7) 0.099
ESBL (+) bacteremia 31 (86.1) 42 (76.4) 0.254
Carbapenem-resistant bacteremia 16 (44.4) 22 (40.0) 0.674
Late-onset infection 12 (33.3) 17 (30.9) 0.808
Septic shock 28 (77.8) 5 (9.1) <0.001
Platelet count < 50,000/mm3 26 (72.2) 13 (23.6) <0.001
Lymphocyte count < 300/mm3 17 (47.2) 15 (27.3) 0.051
Albumin < 30 g/L 11 (30.6) 5 (9.1) 0.009
WBC count > 15,000/mm3 12 (33.3) 15 (27.3) 0.277
Creatinine > 1.5 mg/dL 23 (63.9) 19 (34.5) 0.006
Multivariate analysis
Presence of other concomitant BSIs 0.001 27.074 (3.937–186.210)
Nosocomial infection 0.033 23.963 (1.285–446.991)
Creatinine > 1.5 mg/dL 0.001 24.498 (3.449–173.998)
Septic shock <0.001 160.463 (19.377–1328.832)
ASOT abdominal solid organ transplant, DCD donation after cardiac death, ESBL extended-spectrum beta-lactamase, MDR multidrug-resistant, GNB gram-negative
bacteria, OR odds ratio, CI confidence interval, BSIs bloodstream infections, WBC white blood cells
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recipients, including veno-occlusive disease, drug toxic-
ities, and sepsis, all of which are associated with increased
mortality [66].
Consistent with a previous study [5] based on SOT
recipients with BSI, the present study indicated that
presence of other concomitant BSI was another risk
factor which contributed to mortality. Our previous
studies found polymicrobial was a risk factor for BSI-
related mortality in deceased donor liver or SOT recipi-
ents in the univariate analysis whereas this association
did not remain in the multivariate analysis [51, 53].
Limitation
Our study has several limitations that should be men-
tioned. First, this study was limited by its retrospective
study nature owing to insufficient information, inaccur-
ate written records, or selection biases. In order to avoid
these limitations, prospective studies are needed to
validate the risk factors for mortality proposed by the
current study in future research. Second, this study is
also limited due to the relatively small sample size of
cases and deaths. Therefore, the power of mortality
analyses is limited, as indicated by the wide range of
some of the associated confidence intervals. This is a
common problem in studies evaluating risk factors for
mortality due to MDR organisms. Further well-designed
studies with larger sample size were warranted, espe-
cially studies exploring the association of demographic,
clinical and laboratory variables with additional
outcomes caused by MDR GNB. Third, we did not have
information of patient colonization before transplant-
ation. Fourth, it will be helpful to include more data of
different time points of the creatinine level because, with
time going on, the increased level may be varying. We
intended to include creatinine > 1.5 mg/dl at 1 week
after bacteremia in the univariate analysis. However, Six
recipients died in the first day, three the second day,
four the third day, two the fourth day, and one the fifth
day after MDR GNB, which produced 16 missing values
thus we eventually did not include this variable in the
univariate analysis. Finally, we analyzed a heterogeneous
group of ASOT recipients who may have had their own
specific risk factors for mortality. Although due to the
retrospective data collection, all reported findings should
be interpreted with care, a double-center setting in
different cities in China and a long 13-year period of
study can benefit its generalization of the study findings.
Further strategies to reduce the incidence of posttrans-
plant BSI in ASOT recipients and to control the spread
of MDR gram-negative bacteria, such as the administra-
tion of a short duration of antibiotic prophylaxis, a
timely removal of unnecessary catheters, and avoiding
the overuse of antibiotics and antifungal drugs are
needed to reduce the impact of MDR GNB on allograft
and patient outcomes [68].
Conclusion
MDR GNB was associated with high morbidity and mor-
tality in ASOT recipients, with a predominant causative
organisms being E.coli and A.baumanii. Nosocomial
origin, presence of other concomitant BSI, along with
increased creatinine level and septic shock after ASOT
were the risk factors for MDR GNB-related mortality in
ASOT recipients. Recognition of these factors is useful in
identifying individuals who are at risks of mortality.
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